|
|
 |
|
Viewing report
|
|
|
|
Bayer: Performance, Products, Pipeline and Potential
Espicom Business Intelligence Ltd, Nov 2010, Pages: 136
Bayer is a global enterprise, headquartered in Germany, with core competencies in the fields of healthcare, nutrition and high-tech materials, and organised into three subgroups, namely HealthCare, CropScience and MaterialScience. Following Bayer's acquisition of Schering AG on 23rd June 2006, Schering was renamed Bayer Schering Pharma and its integration into the Pharmaceuticals division of Bayer HealthCare is now under way. Bayer Schering Pharma is expected to contribute to over half the revenues of Bayer HealthCare.
Bayer HealthCare's combined pharmaceuticals business is characterised by a well-balanced portfolio comprised of business units such as oncology, cardiology/haematology and gynaecology. In addition, the combined biotech platform provides a sound basis for further growth, including such products as Schering's Betaseron (interferon beta-1b) and Leukine (sargramostim), together with Bayer’s genetically-engineered Factor VIII Kogenate. Current growth drivers include: Avalox/Avelox (moxifloxacin), Betaferon/Betaseron (interferon beta-1b), Kogenate (Factor VIII), Levitra (vardenafil), Mirena (levonorgestrel), Yasmin (ethinyloestradiol+drospirenone) and Aspirin Cardio. By combining and consolidating the research and development activities of the two companies Bayer has achieved a more focused and balanced pipeline.
The acquisition of Schering AG, the largest corporate transaction in Bayer's history, enhanced the product portfolio and research and development pipeline providing a strong basis on which to build future success for Bayer HealthCare and thus the Bayer Group. Bayer is expecting HealthCare to account for nearly 50 per cent of Group sales in the future.
The integration of Schering is proceeding faster than expected and the acquisition has strengthened the Bayer Group's global market position in the pharmaceutical business as it copes with declining sales for many of its previously top-selling products, specifically Cipro.
Bayer's overall strategy of focusing its portfolio has continued with the divestment of the diagnostics business to Siemens Medical Solutions, followed by the subsidiaries of HC Starck and Wolff Walsrode. Since Bayer has acquired a diagnostics imaging business with the acquisition of Schering, this would seem to be a possible candidate for divestiture in the future.
The withdrawal of Trasylol is a notable setback for the company, especially following the withdrawal of Baycol/Lipobay around six years earlier. Both products managed to reach the market despite safety issues that subsequently led to withdrawal. This has led to company-wide review of Bayer Schering’s development and review processes. These two incidents occurring in such a short space of time could have some impact on Bayer’s profile in the pharmaceutical market.
This new strategic analysis report Bayer: Pipeline, Products, Performance, Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
|
|
|
|
